

# RegenxBio Inc (RGNX) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/R0AD238207FEN.html>

Date: March 2021

Pages: 56

Price: US\$ 125.00 (Single User License)

ID: R0AD238207FEN

## Abstracts

RegenxBio Inc (RGNX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

## Highlights

RegenxBio Inc (RegenxBio), formerly ReGenX Biosciences LLC, is a clinical-stage biotechnology company. It discovers and develops gene therapy for the treatment of various retinal, metabolic, and neurodegenerative diseases. The company develops, commercializes and licenses recombinant adeno-associated virus (AAV) gene therapy. Its products include AAV plasmids, AAV vector reporter systems and custom AAV vectors. The company's gene therapy product candidates deliver genes to cells for addressing genetic defects and enable cells in the body to produce therapeutic proteins or antibodies that act on the disease. RegenxBio employs its proprietary NAV technology platform, a gene delivery technology, to advance its product candidates. RegenxBio is headquartered in Rockville, Maryland, the US.

### RegenxBio Inc Key Recent Developments

Feb 05,2021: REGENXBIO announces presentations at the Angiogenesis, Exudation, and Degeneration 2021 Conference

Feb 01,2021: REGENXBIO announces presentations at the 17th annual WORLDSymposium 2021

Nov 04,2020: REGENXBIO reports third quarter 2020 financial results and operational highlights

Aug 06,2020: REGENXBIO reports second quarter 2020 financial results and operational highlights

Jun 29,2020: Regenxbio announces the resignation from the Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

**Note:** Some sections may be missing if data is unavailable for the company

## Contents

### **SECTION 1 - ABOUT THE COMPANY**

RegenxBio Inc - Key Facts  
RegenxBio Inc - Key Employees  
RegenxBio Inc - Key Employee Biographies  
RegenxBio Inc - Major Products and Services  
RegenxBio Inc - History  
RegenxBio Inc - Company Statement  
RegenxBio Inc - Locations And Subsidiaries  
Head Office  
Other Locations & Subsidiaries

### **SECTION 2 – COMPANY ANALYSIS**

Company Overview  
RegenxBio Inc - Business Description  
R&D Overview  
RegenxBio Inc - Corporate Strategy  
RegenxBio Inc - SWOT Analysis  
SWOT Analysis - Overview  
RegenxBio Inc - Strengths  
RegenxBio Inc - Weaknesses  
RegenxBio Inc - Opportunities  
RegenxBio Inc - Threats  
RegenxBio Inc - Key Competitors

### **SECTION 3 – COMPANY FINANCIAL RATIOS**

Financial Ratios - Capital Market Ratios  
Financial Ratios - Annual Ratios  
Performance Chart  
Financial Performance  
Financial Ratios - Interim Ratios  
Financial Ratios - Ratio Charts

### **SECTION 4 – COMPANY’S LIFESCENCES FINANCIAL DEALS AND ALLIANCES**

RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021  
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021  
RegenxBio Inc, Recent Deals Summary

## **SECTION 5 – COMPANY’S RECENT DEVELOPMENTS**

Feb 05, 2021: REGENXBIO announces presentations at the Angiogenesis, Exudation, and Degeneration 2021 Conference

Feb 01, 2021: REGENXBIO announces presentations at the 17th annual WORLDSymposium 2021

Nov 04, 2020: REGENXBIO reports third quarter 2020 financial results and operational highlights

Aug 06, 2020: REGENXBIO reports second quarter 2020 financial results and operational highlights

Jun 29, 2020: Regenxbio announces the resignation from the Board of Directors

May 01, 2020: REGENXBIO To Host Conference Call on May 7 to Discuss First Quarter 2020 Financial Results and Recent Operational Highlights

Apr 01, 2020: REGENXBIO and Ultragenyx announce new license agreement for use of NAV technology platform for the treatment of Rare Metabolic Disorder

Feb 26, 2020: REGENXBIO reports fourth quarter and full-year 2019 financial results and operational highlights

Jan 09, 2020: REGENXBIO reports continued progress across programs in year-end 2019 corporate update

## **SECTION 6 – APPENDIX**

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

RegenxBio Inc, Key Facts  
RegenxBio Inc, Key Employees  
RegenxBio Inc, Key Employee Biographies  
RegenxBio Inc, Major Products and Services  
RegenxBio Inc, History  
RegenxBio Inc, Subsidiaries  
RegenxBio Inc, Key Competitors  
RegenxBio Inc, Ratios based on current share price  
RegenxBio Inc, Annual Ratios  
RegenxBio Inc, Annual Ratios (Cont...1)  
RegenxBio Inc, Annual Ratios (Cont...2)  
RegenxBio Inc, Interim Ratios  
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021  
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021  
RegenxBio Inc, Recent Deals Summary  
Currency Codes  
Capital Market Ratios  
Equity Ratios  
Profitability Ratios  
Cost Ratios  
Liquidity Ratios  
Leverage Ratios  
Efficiency Ratios

## List Of Figures

### LIST OF FIGURES

RegenxBio Inc, Performance Chart (2016 - 2020)

RegenxBio Inc, Ratio Charts

RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

RegenxBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021



## I would like to order

Product name: RegenxBio Inc (RGNX) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/R0AD238207FEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R0AD238207FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970